Drugs with Patent Challenge Regulatory Exclusivity
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Exclusivity Expiration | Patented / Exclusive Use |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Alkem Labs Ltd | TOPIRAMATE | topiramate | SOLUTION;ORAL | 217795-001 | Oct 31, 2024 | AB | RX | No | No | ⤷ Get Started Free | PATENT CHALLENGE |
| Baxter Hlthcare Corp | ACETAMINOPHEN | acetaminophen | SOLUTION;INTRAVENOUS | 214331-002 | May 21, 2025 | RX | No | Yes | ⤷ Get Started Free | PATENT CHALLENGE | |
| Natco Pharma Ltd | BOSENTAN | bosentan | TABLET, FOR SUSPENSION;ORAL | 213154-001 | Feb 5, 2025 | AB | RX | No | No | ⤷ Get Started Free | PATENT CHALLENGE |
| Fresenius Kabi Usa | EPHEDRINE SULFATE | ephedrine sulfate | SOLUTION;INTRAVENOUS | 218271-001 | Mar 11, 2025 | AP2 | RX | No | No | ⤷ Get Started Free | PATENT CHALLENGE |
| Fresenius Kabi Usa | EPHEDRINE SULFATE | ephedrine sulfate | SOLUTION;INTRAVENOUS | 218271-002 | Mar 11, 2025 | AP2 | RX | No | No | ⤷ Get Started Free | PATENT CHALLENGE |
| Teva Pharms | LIRAGLUTIDE | liraglutide | SOLUTION;SUBCUTANEOUS | 214568-001 | Aug 27, 2025 | AP2 | RX | No | No | ⤷ Get Started Free | PATENT CHALLENGE |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Exclusivity Expiration | >Patented / Exclusive Use |
